Spinal cord lipoma

Summary

Spinal cord lipoma (MONDO:0001790) is a disease and 1 clinical trial. A subtype of central nervous system lipoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord lipoma
Mondo ID	MONDO:0001790
Orphanet	645276
DOID	DOID:13743
NCIT	C4619
SNOMED CT	189017000
UMLS	C0347446
MedGen	91131
GARD	0023013
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	no

Also known as: lipoma of spinal cord · spinal cord lipoma

Disease family

This is a subtype of central nervous system lipoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › nervous system benign neoplasm › central nervous system organ benign neoplasm › central nervous system lipoma › spinal cord lipoma

Related subtypes (2): cerebral hemisphere lipoma, central nervous system hibernoma

Subtypes (2): intramedullary non-dysraphic spinal cord lipoma, dysraphic spinal cord lipoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02722681	Not specified	UNKNOWN	Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma.